KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) EPS (Basic): 2013-2025

Historic EPS (Basic) for Xenon Pharmaceuticals (XENE) over the last 12 years, with Sep 2025 value amounting to -$1.15.

  • Xenon Pharmaceuticals' EPS (Basic) fell 41.98% to -$1.15 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.89, marking a year-over-year decrease of 37.94%. This contributed to the annual value of -$3.01 for FY2024, which is 10.26% down from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' EPS (Basic) stood at -$1.15, which was down 7.48% from -$1.07 recorded in Q2 2025.
  • Xenon Pharmaceuticals' EPS (Basic)'s 5-year high stood at -$0.35 during Q1 2022, with a 5-year trough of -$1.15 in Q3 2025.
  • Its 3-year average for EPS (Basic) is -$0.80, with a median of -$0.75 in 2024.
  • Its EPS (Basic) has fluctuated over the past 5 years, first crashed by 10,392.24% in 2021, then grew by 16.67% in 2022.
  • Quarterly analysis of 5 years shows Xenon Pharmaceuticals' EPS (Basic) stood at -$0.48 in 2021, then decreased by 18.75% to -$0.57 in 2022, then fell by 12.28% to -$0.64 in 2023, then crashed by 31.25% to -$0.84 in 2024, then crashed by 41.98% to -$1.15 in 2025.
  • Its EPS (Basic) stands at -$1.15 for Q3 2025, versus -$1.07 for Q2 2025 and -$0.83 for Q1 2025.